Drivers affecting Senzime’s market growth
Increasing number of surgeries
There is an increasing number of surgeries using neuromuscular blocking agents which is a target market for Senzime. The accuracy and ease-of-use of the TetraGraph drives adoption of more novel technologies.
Growing number of guidelines and hospital protocols
More and more national guidelines and hospital protocols are driving the use of objective neuromuscular monitoring.
Hospitals are shifting towards Personalized and improved care, with technologies that can be used during all types of surgeries.
High number of complications
Around 60% of all patients receiving neuromuscular blocking agents are extubated too early, leading to unnecessary complications. With accurate monitors available in every operating theatre and used on every patient this can be dramatically reduced.